Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Liquidia Corp Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/10/2023 8-K Quarterly results
Docs: "Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update MORRISVILLE, N.C., August 10, 2023"
07/27/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ Inhalation Powder"
07/24/2023 8-K Quarterly results
07/17/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
06/29/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
06/16/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
06/08/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
05/04/2023 8-K Quarterly results
Docs: "Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update MORRISVILLE, N.C., May 4, 2023",
"Liquidia Corporation script for the conference call and online webcast held on May 4, 2023"
04/03/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications"
03/22/2023 8-K Other Events  Interactive Data
03/16/2023 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits ...
Docs: "Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update"
01/30/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
01/09/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million -"
12/05/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension -"
11/25/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
11/08/2022 8-K Quarterly results
Docs: "Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update"
10/28/2022 8-K Quarterly results
07/19/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent"
07/01/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
04/18/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement by and between Liquidia Corporation and BofA Securities, Inc., as representative of the underwriters named therein",
"Opinion of DLA Piper LLP (US)",
"Liquidia Announces Proposed Offering of Common Stock",
"Liquidia Announces Pricing of Public Offering of Common Stock MORRISVLLE, N.C., April 12, 2022 - Liquidia Corporation announced the pricing of an underwritten public offering of 9,803,922 shares of its common stock at a public offering price of $5.10, for total gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and expenses payable by Liquidia. All of the shares in the offering will be sold by Liquidia. In addition, Liquidia has granted the underwriters a 30-day option to purchase up to an additional 1,470,588 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on April 18, 2022, subject to customary closing conditions. BofA Securities is acting as the sole b...",
"Liquidia Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option"
04/08/2022 8-K Other Events  Interactive Data
03/17/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update"
03/14/2022 8-K Quarterly results
02/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "6. COVENANT NOT TO SUE . Employee will not sue Releasees on any matters relating to Employee’ s employment arising before the execution of this Agreement or join as a party with others who may sue Releasees on any such claims; provided, however, this Section 6 will not: bar claims for workers’ compensation or unemployment benefits referenced in Section 5 above, bar a challenge under the Older Workers Benefit Protection Act of 1990 to the enforceability of the waiver and release of ADEA claims set forth in this Agreement, or bar a claim for breach of any agreement between Employee and the Company that is not superseded by this Agreement, including without limitation any claims for breach of this Agreement; or apply when prohibited by law, including as set forth in Section 7 below. If Employ..."
01/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "LIQUIDIA CORPORATION",
"GLOSSARY"
01/11/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "WARRANT TO PURCHASE STOCK",
"WARRANT TO PURCHASE STOCK",
"WARRANT TO PURCHASE STOCK This WARRANT TO PURCHASE STOCK is issued as of the issue date set forth on Schedule I hereto by the company set forth on Schedule I hereto to INNOVATION CREDIT FUND VIII-A, L.P. in connection with that certain Amended and Restated Loan and Security Agreement of even date herewith among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Company . The parties agree as follows: SCHEDULE I. WARRANT PROVISIONS . Warrant Section Warrant Provision Recitals – “Issue Date” January 7, 2022 Recitals – “Company” Liquidia Corporation, a Delaware corporation 1.1 – “Class” Common Stock, $0.001 par value per share 1.1– “Exercise Price” $5.14 1.2 – “Shares” 62,500 6.1 – “Expiration Date” January 6, 2032 SECTION 1. RIGHT TO PURCHASE SHARES . 1.1 Grant of Right . For...",
"SCHEDULE I LSA PROVISIONS",
"Liquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40.0 Million"
12/29/2021 8-K Quarterly results
12/13/2021 8-K Quarterly results
11/19/2021 8-K Other Events  Interactive Data
11/08/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FDA Grants Tentative Approval for Liquidia’ s YUTREPIA™ inhalation powder - First dry-powder formulation of treprostinil to meet criteria required for FDA approval - Final FDA approval may occur in October 2022 or earlier upon resolution of on-going litigation - Conference call and webcast scheduled for today at 9:00 a.m. Eastern Standard Time"
10/12/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy